TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Area under the plasma concentration-time curve from time zero extrapolated to infinite time [AUC(0-inf)]
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Target Vessel Revascularization at 9 Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Trough Forced Expiratory Volume in 1 Second (Trough FEV1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: DNA damage in lymphocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Coronary Artery Calcification
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Attention Deficit Hyperactivity Disorder (ADHD) Rating Scale (ADHD RS-IV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vessel dissection or perforation
Endpoint domain: Adverse events/effects
Primary endpoint: Grade 3 or Grade 4 hemorrhage
Endpoint domain: Adverse events/effects
Primary endpoint: Cerebrovascular accident
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction in the systolic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Level of PTSD symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of participants who complete 6-month outcome assessments
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Communication Outcomes
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Ductal closing rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Patients Experiencing Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Neonatal necrotizing enterocolitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Clinical test of sensory organization and balance (CTSIB)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cortisol change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Viral Decline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of valvulopathies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Short Term Efficacy of Antibiotic Treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Long Term Efficacy of Antibiotic Treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of Antibiotic treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Apolipoprotein B bound to erythrocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of plot samples collected
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in Uncorrected Distance Visual Acuity (UDVA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Uncorrected Near Visual Acuity (UNVA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Childhood Depression Rating Scale -Revised
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Modified Psoriasis Assessment severity index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Days on NCPAP or Mechanical Ventilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Area Under the Analyte Concentration-Time Curve (AUC[0-last])
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Analyte Concentration-Time Curve (AUC[0-infinity])
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serological responses to pneumococcal serotypes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Concentration of Glutamine and Myoinositol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional MRI Activation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Lower extremity functioning
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Accuracy of contrast enhanced ultrasound (CEUS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Performance of MRI vs TRUS in fiducial marker insertion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number of Participants With 4-fold or Greater HAI Antibody Titer Increases 8 Days Following the First Dose of H1N1 Vaccine (Ages 18-64)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Participants With 4-fold or Greater HAI Antibody Titer Increases 21 Days Following the First Dose of H1N1 Vaccine (Ages 18-64)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Safety Data Score
Endpoint domain: Adverse events/effects
Primary endpoint: 3 month treatment response of metastases
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in Microbial Phylum Abundance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Spontaneous closure rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Body pain pre-biopsy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Breast pain pre-biopsy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Body pain post-biopsy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Breast pain post-biopsy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Successful identification of sentinel nodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Bone metabolic markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change from Baseline in voice handicap index (VHI)-10 scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy rate based on global assessment of efficacy
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: clinical accuracy of the XACT system
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of hospital days for all causes
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Incidence of pneumonia or lower respiratory tract infection
Endpoint domain: Adverse events/effects
Primary endpoint: Time of onset of the first respiratory exacerbation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Amount of Pain Medication Used
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of Subjects Who Need Additional Pain Medication and/or Refill
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Reliability to detect leukocoria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Dose-Limiting Toxicities (DLT) of HX009
Endpoint domain: Adverse events/effects
Primary endpoint: Transcriptome of B cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Immunoglobulin receptors of B cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Surgeon's Assessment of Overall Satisfaction With the Surgical Conditions
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Utilization of maternal and child health (MCH) services
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Use of PMTCT interventions
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Ottawa Bowel Preparation Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Treatment Failures
Endpoint domain: Adverse events/effects
Primary endpoint: best overall response rate (BOR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Success rate of spontaneous tube positioning
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Asthma symptom free days
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Diabetes Quality of Life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Identification of TSC biomarker/s
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time-weighted Average Change in Nasal RSV Load
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Coagulation assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of blood samples collected
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: The Morphine Equivalent of Opioid Use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bloodloss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Response rate to GAMEC-S or GAMEC-A
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline in Schramek's Grade
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection of specific genetic alterations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in glycemic regulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Prostate biopsy outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change From Baseline in Average Number of T1 Contrast-enhanced Lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: modifications of treatments administered
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: change in the rate of treatment administration
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: number of cures administered
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: change of modality of administration
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Cancer Antigen-specific Immune Responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Reduction of the Facial Wrinkle Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Patient Assessed Frown-line Improvement
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: IBS-symptom severity scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with live donor kidney transplants
Endpoint domain: Mortality/survival
Primary endpoint: Feasibility of mapping and ablating ventricular tachycardias
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Area Under the Plasma Concentration-time Curve for Ticagrelor (AUC 0-12h)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Coronary physiology changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Length of inpatient stay
Endpoint domain: Resource use
Primary endpoint: Maximal Tolerated Dose (MTD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Postoperative myocardial necrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Postoperative kidney injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Fecal metabolome profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma metabolome profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUCΔBG0-2h
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: AUClispro 0-30min
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Boston Bowel Preparation Quality Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Time to first pulmonary exacerbation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Time to goal MAP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change of trough seated diastolic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Index of cerebrovascular autoregulation (Mx)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Rate of CTCAE acute grade 3 or higher adverse effects
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in Glycated hemoglobin (HbA1c) values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Collection of CD34+PBSC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Rate of chromosomal imbalances
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: clinical monitoring of blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: number of subjects with adverse events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Baseline-corrected area under the total T4 serum concentration-time curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Area under the semaglutide plasma concentration-time curve during a dosing interval
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Brain Imaging
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Percentage of Subjects Meeting Exit Criteria
Endpoint domain: Mortality/survival
Primary endpoint: Pain of Lidocaine Injection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-reported Satisfaction With the Screening Process
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percentage of Participants With an Occurrence of at Least One Grade 3 or Higher Adverse Event (AE)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants Diagnosed With HIV Infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Cumulative 24 Hour Oral Morphine Equivalent Consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Motor Power - Peak Force as measured by a dynamometer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Changes in Numeric Rating Scale (NRS)
Endpoint domain: Life impact
Endpoint subdomain: Pain
Primary endpoint: Percentage of Subjects With Best Overall Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Impedance changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: hemorrhage growth
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Pharmacokinetics (PK) of CT-P13
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Level of oxysterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Level of alpha- and gamma-tocopherol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in patient's quality of living over time
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Estimate and compare the hazard ratios and median survival before and after 1 year from enrollment
Endpoint domain: Mortality/survival
Primary endpoint: Hot flash frequency and severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of correct responses in odor discrimination
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: motor threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: amplitude
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Receipt of palliative care consult
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Disability Questionnaire Arm, Shoulder and Hand (DASHe)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in Maximal Platelet Aggregation in Response to Clopidogrel
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in Maximal Platelet Aggregation in Response to Ticagrelor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: severity of epistaxis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration Curve (AUC) of Testosterone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Drug Concentration (Cmax) of Testosterone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy of solifenacin succinate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Immunological markers of prognosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Initial Cervical Dilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Percent of Patients that respond to Treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Who Received First Line Chemotherapy According to National Trial or Treatment Guideline
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Intraocular lens rotation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Area under the plasma/serum/blood drug concentration-time curve in steady-state of Telmisartan and Amlodipine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum concentration of drug in plasma/serum/blood in steady-state of Telmisartan and Amlodipine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma/serum/blood drug concentration-time curve in steady-state of Rosuvastatin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum concentration of drug in plasma/serum/blood in steady-state of Rosuvastatin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mild-to-moderate sedation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Yale Preoperative Anxiety Scale (mYPAS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Synaptic changes in psychiatric disorders
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Synaptic density at greatest anti-depressant response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rates of eligible patients consented and randomized
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Proportion of Patients With Complete TMA Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post-Prandial Metabolism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Max. plasma concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Half-life of drug elimination
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Program attendance
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Rate of Moderate to High Arsenic Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Depressive Recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Clinically Significant ECG Abnormalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percent Change From Baseline in 24-hour Urine Protein:Creatinine Ratio (UPCR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Glasgow Outcome Scale-Extended
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Total Net D12FS Caries Increment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Allergen PD20 FEV1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Three consecutive MOAA/S scores ≤4
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Completing the procedure without requiring alternative sedative medication
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Without requiring manual or mechanical ventilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Rate of structural Valve Deterioration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of participants with fistula usable without intervention
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes